HARBOR INVESTMENT ADVISORY, LLC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 220 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.

Quarter-by-quarter ownership
HARBOR INVESTMENT ADVISORY, LLC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q1 2023$26,426
-34.7%
659
-24.5%
0.00%
-33.3%
Q4 2022$40,446
+12.4%
8730.0%0.01%0.0%
Q3 2022$36,000
-30.8%
8730.0%0.01%
-25.0%
Q2 2022$52,000
-5.5%
873
+15.6%
0.01%
+14.3%
Q1 2022$55,000
-12.7%
7550.0%0.01%
-12.5%
Q4 2021$63,000
-7.4%
7550.0%0.01%
-11.1%
Q3 2021$68,000
-5.6%
7550.0%0.01%
-10.0%
Q2 2021$72,000
-24.2%
755
-9.0%
0.01%
-28.6%
Q1 2021$95,000
-24.0%
830
-8.1%
0.01%
-30.0%
Q4 2020$125,000
+101.6%
903
+20.4%
0.02%
+66.7%
Q3 2020$62,000
+77.1%
750
+69.7%
0.01%
+71.4%
Q2 2020$35,000
+75.0%
4420.0%0.01%
+40.0%
Q1 2020$20,0004420.01%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q3 2021
NameSharesValueWeighting ↓
First Light Asset Management, LLC 441,159$39,788,0002.62%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 103,100$9,286,0002.24%
Rock Springs Capital Management LP 801,109$72,252,0001.52%
Avidity Partners Management LP 455,000$41,036,0000.91%
Motley Fool Asset Management LLC 134,357$12,118,0000.79%
FEDERATED HERMES, INC. 3,987,032$359,590,0000.68%
EMERALD ADVISERS, LLC 196,124$17,688,0000.64%
Ergoteles LLC 128,100$11,553,0000.42%
Tekla Capital Management LLC 140,726$12,692,0000.41%
Beck Bode, LLC 14,990$1,352,0000.38%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders